Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 3/28/2019 |
| Start Date: | April 23, 2018 |
| End Date: | May 15, 2020 |
| Contact: | Debbie Griffin, RN |
| Email: | dgriffin3@kumc.edu |
| Phone: | 913-588-7691 |
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like
protein) in the urine that is changed after treatment of hydralazine.
protein) in the urine that is changed after treatment of hydralazine.
Inclusion Criteria:
- Confirmed diagnosis of ADPKD
- estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73m^2
Exclusion Criteria:
- History of systemic lupus erythematous or other rheumatologic disorder
- Baseline anti-nuclear antibody (ANA) >1:80 for females and >1:40 for males
- Blood pressure < 120/80 without anti-hypertensive
- Angina pectoris or myocardial infarction in the last 6 months
- Liver disease
- Allergy to hydralazine
We found this trial at
1
site
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
